157 E 32nd St. New York, NY 10016 212-689-6791

 

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes Observational Study at MHOA

The objectives of this molecular profiling protocol are to describe current treatment patterns and consequences from first-line treatment regimes and subsequent strategies in patients with Classic Hodgkin Lymphoma (cHL), to evaluate clinical outcomes and quality of life, and to characterize tumor and host immunophenotypic/molecular profiles.

This is an observational, non-interventional multi-center phase 4 study that will enroll patients diagnosed and treated for Hodgkin Lymphoma.

MHOA Principle Investigator
Alec Goldenberg, M.D. 

For additional information contact:
Phenoia Browne, Clinical Trials Coordinator
Phone: 212-689-6791 ext 228
Email: clinicaltrials@mhony.com

AML- FLT3

Now enrolling of patients on a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are….

Read More

AML- FLT3/IDT

Now enrolling patients for a phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215)…

Read More

Mantle Cell Lymphoma

Now enrolling patients in a phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of…

Read More

CLL

Now enrolling patients for the InformCLL Registry, which is to characterize and describe treatment patterns for those initiating treatment with…

Read More